A beneficial association between metformin and mortality has been already described both in selected patients with chronic heart failure [11], liver disease [12, 13], mild-to-moderate kidney failure [14] which are usual contraindications, and in ICU patients [3].
The doctors have described the man as a diabetic who was in dire condition before the implant with terminal heart failure, a moderate degree of kidney failure and abnormally high pressure in blood vessels in his lungs.
The QKidney score (moderate or severe kidney failure) showed the observed risk was lower than the predicted risk.
The effect was more marked for moderate or severe kidney failure where the incidence rates for CPRD were approximately 25% lower than those for QResearch in women and 16% lower in men.
Incident events relating to seven different risk prediction scores: QRISK2 (cardiovascular disease); QStroke (ischaemic stroke); QDiabetes (type 2 diabetes); QFracture (osteoporotic fracture and hip fracture); QKidney (moderate and severe kidney failure); QThrombosis (venous thromboembolism); QBleed (intracranial bleed and upper gastrointestinal haemorrhage).
The product is currently marketed worldwide for cats and dogs with moderate-to-severe kidney failure (Azodyl, Vetoquinol SA, http://www.vetoquinol.com/).
A dosage reduction of 25%, 50 % and 75 is recommended in patients with mild (stage 3), moderate (stage 4) and severe kidney failure (stage 5) respectively.
Both algorithms were well calibrated in the THIN cohort as shown by the close correspondence between observed and predicted values in the calibration graphs across tenths of predicted risk both for moderate-severe CKD and End Stage Kidney Failure.
We have developed and validated two new risk prediction algorithms designed to predict risk of moderate-severe CKD and End Stage Kidney Failure in primary care which have the potential to identify high risk patients who might benefit from more detailed assessment, closer monitoring or interventions to reduce their risk.
Patients were classified according to Kidney Disease Outcomes Quality Initiative (KDOQI) stages and CKD was defined as the presence of CKD with KDOQI stage 3 or higher (a moderate or severe reduction in GFR or kidney failure).
